Skip to main content

Table 3 Indirect comparison of progression free survival

From: Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

HR of PFS (95% CI)
 2.70 (1.79–4.08) * GEM-NAB   
 3.21 (2.10–4.89) * 1.19 (0.93–1.51) FOLFIRINOX  
 3.22 (1.95–5.30) * 1.19 (0.85–1.67) 1.00 (0.78–1.29) mFOLFIRINOX
  1. Abbreviation: HR: hazard ratio; PFS: progression-free survival; CI: confidence interval; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX
  2. Notes: Comparisons between treatments were read from left to right, and the estimate (HR) with 95% CI for a given comparison was read in the intersection of two treatments. The value of estimates higher than 1 indicated that column-defining treatment had better efficacy
  3. * Denotes p-value < 0.05